Literature DB >> 27042496

Effect of Heparin on Coagulation Tests: A Comparison of Continuous and Bolus Infusion in Haemodialysis Patients.

Ali Akbar Nasiri1, Sudabeh Ahmadidarrehsima2, Abbas Balouchi2, Hosein Shahdadi3, Mahdiye Poodine Moghadam3.   

Abstract

INTRODUCTION: Haemodialysis is one of the most conventional treatments of chronic renal failure. The risk of clot formation is high during haemodialysis due to regular contact of blood with the surfaces of foreign objects such as catheters, dialyzers' membrane, and other materials used for dialysis. Therefore, to prevent clot formation during haemodialysis, the dialysis system requires anticoagulation; this is usually done by heparin. AIM: The present study aimed to compare two heparinization methods and determine the proper impacts of these methods.
MATERIALS AND METHODS: In this quasi-experimental study, 80 haemodialysis patients covered by the dialysis center of Amir-al-momenin Hospital of Zabol were studied in two 40-member groups of heparin therapy methods of bolus injection and continuous infusion. PT and PTT were measured in blood samples collected from all patients before starting haemodialysis. The first group received 3000 units of heparin once the haemodialysis machine started to work and 2000 units of heparin two hours later as bolus injection. In the second group, 1500 units of heparin was injected at the start of dialysis after then, 5000 units of heparin (one mL) were mixed with 11 mL of distilled water and infused using a heparin injection pump up to half an hour before the end of dialysis. At 30 minutes after starting dialysis and at the end of 4 hours of haemodialysis, PT and PTT were measured and compared between the two groups.
RESULTS: According to the results, the mean partial thromboplastin time in the bolus and continuous heparin-receiving group was 41.75±6.29 and 37.90±4.77, respectively, which was statistically significant (p=0.036). But PT was 14.45±1.82 in the bolus heparin group and 13.95±1.39 in the continuous heparin group, which was not significant according to the results of independent t-test (p=0.336).
CONCLUSION: The results indicated a statistically significant difference between the bolus heparin injection and the continuous heparin infusion groups in terms of coagulation tests in haemodialysis patients (p=0.036). Therefore, given the effects of heparin on coagulation, it was more effective in the bolus heparin group than the continuous infusion group. It is recommended to use the bolus method for heparin therapy during haemodialysis.

Entities:  

Keywords:  Continuous heparin infusion; Heparin bolus injection; PT; PTT

Year:  2016        PMID: 27042496      PMCID: PMC4800562          DOI: 10.7860/JCDR/2016/18476.7231

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  19 in total

Review 1.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

Review 2.  Unfractionated heparin for hemodialysis: still the best option.

Authors:  Robert E Cronin; Robert F Reilly
Journal:  Semin Dial       Date:  2010 Sep-Oct       Impact factor: 3.455

3.  Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets.

Authors:  S Sagedal; A Hartmann; K Sundstrøm; S Bjørnsen; F Brosstad
Journal:  Nephrol Dial Transplant       Date:  2001-05       Impact factor: 5.992

4.  Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens.

Authors:  Alaa Sabry; Moammer Taha; Mamdouh Nada; Fawzan Al Fawzan; Khalid Alsaran
Journal:  Blood Coagul Fibrinolysis       Date:  2009-01       Impact factor: 1.276

5.  Heparinisation in chronic haemodialysis treatment: bolus injection or continuous homogeneous infusion?

Authors:  J Y De Vos; H Marzoughi; R Hombrouckx
Journal:  EDTNA ERCA J       Date:  2000 Jan-Mar

Review 6.  Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Theodore E Warkentin; Andreas Greinacher
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.

Authors:  Benjamin Guillet; Nicolas Simon; Jérôme José Sampol; Anne-Marie Lorec-Penet; Henri Portugal; Yvon Berland; Bertrand Dussol; Philippe Brunet
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

8.  Design of the rivaroxaban for heparin-induced thrombocytopenia study.

Authors:  Lori-Ann Linkins; Theodore E Warkentin; Menaka Pai; Sudeep Shivakumar; Rizwan A Manji; Philip S Wells; Mark A Crowther
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

9.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

10.  Heparinization for routine hemodialysis.

Authors:  R A Ward
Journal:  Adv Ren Replace Ther       Date:  1995-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.